Ecthyma gangrenosum (EG) is a rare skin infection classically associated with Pseudomona aeruginosa. It can be a potentially fatal systemic infection and can be a manifestation of an underlying ...

A female infant presented was admitted to our paediatric service with a genital ulcer. She is an only child of no consanguineous parents. The pregnancy was well managed without incident, and delivery ...

The clinical apperance of cutaneous mucormycosis is generally non-spesific. It may arise as a painful erythematous induration of skin resembling common phlebitis. It may progress to a necrotizing ...

InflaRx has taken the difficult decision to abandon its drug development programme, vilobelimab, for rare inflammatory skin disorder pyoderma gangrenosum (PG), a move that has pummelled its share ...

Backers of Jena, Germany-based Inflarx NV have turned their attention to the rest of the pipeline after the stock-jolting news from an independent data monitoring committee (DMC) responsible for the ...

InflaRx Announces Outcome of Interim Analysis for Vilobelimab Phase 3 Trial in Pyoderma Gangrenosum. 28.05.25 07:30 GlobeNewswire ...

JENA, Germany, May 28, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced that ...

InflaRx Announces Outcome of Interim Analysis for Vilobelimab Phase 3 Trial in Pyoderma Gangrenosum Provided by GlobeNewswire May 28, 2025, 5:30:00 AM.

After a poor showing of its COVID med vilobelimab in a rare skin disorder trial, German drugmaker InflaRx is going back to the drawing board.

JENA, Germany, May 28, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced that ...

SPOKANE COUNTY, Wash. — A Spokane County man faces potential termination from his county job while he battles a rare and deadly skin disease that has kept him from working for several months.